BIOS Fund I, LP's Form 4 filing
Actuate Therapeutics, Inc. (ACTU) · filed Jun 30, 2025
- Accession no.
- 0001104659-25-063992
- Filed
- Jun 30, 2025, 1:02 PM ET
- Trade date
- Jun 27, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $500.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BIOS Fund I, LPCIK 0001697316 | Director, 10% Owner |
| BIOS Fund I QP, LPCIK 0001700297 | Director, 10% Owner |
| BIOS Fund II, LPCIK 0001714576 | Director, 10% Owner |
| BIOS Fund II QP, LPCIK 0001716869 | Director, 10% Owner |
| BIOS Fund II NT, LPCIK 0001728851 | Director, 10% Owner |
| Cavu Management, LPCIK 0001813270 | Director, 10% Owner |
| Cavu Advisors, LLCCIK 0001813310 | Director, 10% Owner |
| Bios Equity Partners II, LPCIK 0001813313 | Director, 10% Owner |
| Bios Equity Partners, LPCIK 0001813314 | Director, 10% Owner |
| Kreis Leslie W.CIK 0001813316 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | Common Stock | PPurchaseAcquired | +71,428 | $7.00 | +$499,996 | 196,428 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | Common Stock | PPurchaseAcquired | +71,428 | $0.00 | $0 | 71,428 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Exhibit 24 - Power of Attorney Each of the reporting persons may be deemed a "director by deputization" as the result of Aaron G.L. Fletcher's position as a director of the Issuer. This Form 4 is the second of three Forms 4 filed relating to the same event. The Form 4 has been split into three filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons. The first Form 4 was filed by Aaron G.L. Fletcher as the designated filer. The third Form 4 will be filed by Bios Equity COF, LP as the designated filer.